PeraHealth, Inc

perahealth.com

PeraHealth is transforming healthcare through the intelligent use of data. By leveraging the Rothman Index, a validated patient acuity score, PeraHealth’s clinical surveillance software solutions enable healthcare providers to identify at-risk patients sooner for earlier intervention. They also help providers determine when to discharge patients; prioritize patient bedside visits and nursing assignments; improve documentation accuracy and timeliness, optimize ICU bed use, and identify opportunities for palliative care consults. More than 80 leading hospitals and care providers, such as Yale New Haven Health System, Houston Methodist, Children’s Hospital of Philadelphia and Memorial Sloan Kettering Cancer Center, utilize PeraHealth’s real-time, predictive analytics to improve quality and reduce costs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Health Technology

MICROBOT MEDICAL ANNOUNCES STRATEGIC COLLABORATION WITH STRYKER CORPORATION TO DEVELOP THE LIBERTY® ROBOTIC SYSTEM FOR NEUROVASCULAR APPLICATIONS

Microbot Medical | December 28, 2021

news image

Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the L...

Read More

3 TRENDS DRIVING HEALTHCARE MERGERS & ACQUISITIONS ACTIVITY IN 2020

HIT Consultant | January 22, 2020

news image

The New Year often brings with it an essence of transformation. This year, U.S. healthcare’s metamorphosis is now more than a decade old, as it continues to shed its antiquated legacy systems and siloes to embrace a different kind of entity-one that hopes to establish weight in value-based care at a scale robust enough to substantiate it. Healthcare providers are aiming to achieve that life cycle through a series of partnerships as well as mergers and acquisitions, which have become increa...

Read More

Digital Healthcare, Medical Devices

GAYLORD SPECIALTY HEALTHCARE FIRST IN NATION TO ADOPT GROUND-BREAKING PHARYNGEAL ELECTRICAL STIMULATION TECHNOLOGY TO TREAT PATIENTS WITH DYSPHAGIA

Prnewswire | May 10, 2023

news image

Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke patients. Dysphagia – or the difficulty or inability to swallow – affects millions worldwide and is a common diagnosis among adult patients at long-term acute care hospitals, including Gaylord Hospital. D...

Read More

Health Technology

SANDOZ ANNOUNCES FURTHER PROGRESS ON ITS BIOSIMILAR PIPELINE, WITH RELEASE OF POSITIVE RESULTS FOR DENOSUMAB INTEGRATED PHASE I/III CLINICAL TRIAL

Novartis Pharma AG | September 19, 2022

news image

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individ...

Read More
news image

Health Technology

MICROBOT MEDICAL ANNOUNCES STRATEGIC COLLABORATION WITH STRYKER CORPORATION TO DEVELOP THE LIBERTY® ROBOTIC SYSTEM FOR NEUROVASCULAR APPLICATIONS

Microbot Medical | December 28, 2021

Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the L...

Read More
news image

3 TRENDS DRIVING HEALTHCARE MERGERS & ACQUISITIONS ACTIVITY IN 2020

HIT Consultant | January 22, 2020

The New Year often brings with it an essence of transformation. This year, U.S. healthcare’s metamorphosis is now more than a decade old, as it continues to shed its antiquated legacy systems and siloes to embrace a different kind of entity-one that hopes to establish weight in value-based care at a scale robust enough to substantiate it. Healthcare providers are aiming to achieve that life cycle through a series of partnerships as well as mergers and acquisitions, which have become increa...

Read More
news image

Digital Healthcare, Medical Devices

GAYLORD SPECIALTY HEALTHCARE FIRST IN NATION TO ADOPT GROUND-BREAKING PHARYNGEAL ELECTRICAL STIMULATION TECHNOLOGY TO TREAT PATIENTS WITH DYSPHAGIA

Prnewswire | May 10, 2023

Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke patients. Dysphagia – or the difficulty or inability to swallow – affects millions worldwide and is a common diagnosis among adult patients at long-term acute care hospitals, including Gaylord Hospital. D...

Read More
news image

Health Technology

SANDOZ ANNOUNCES FURTHER PROGRESS ON ITS BIOSIMILAR PIPELINE, WITH RELEASE OF POSITIVE RESULTS FOR DENOSUMAB INTEGRATED PHASE I/III CLINICAL TRIAL

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us